Briefs
This advisory brief incorporates learnings from TGaS Advisors’ 2023 Spring Summit, which brought together the industry’s top commercial operations, market access and medical affairs executives to discuss the hottest trends, address concerns and prepare for future challenges.
Leaders from more than 100 emerging, mid tier and large tier biopharmaceutical companies attended function specific sessions. Leaders shared perspectives, made recommendations and collectively thought through alternative paths for key decisions for today and beyond.
Complete the form below to access the full…
Read Now
Webinars
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.
Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each…
Watch Now
Blog
Published June 16, 2023
Last month, Trinity attended the ISPOR 2023 conference in Boston. The main theme of the conference was “Impacting Innovation, Value and Healthcare Decision Making”, which facilitated unique discussions and workshops across different stakeholders in the life sciences, including manufacturers, regulatory leaders and health economists. Topics included discussions on the role of artificial intelligence (AI) in HEOR, innovation in evidence generation, the latest trends in health policy and a myriad of others.
A highlight for Trinity Life Sciences was presenting 12…
Read Now
White Papers
Pharmaceutical companies that are seeking ways to engage and partner with integrated delivery networks must understand this: IDNs are evolving in ways that have a profound effect on how healthcare is managed, what care paths are followed and which populations are carved out for special attention.
TGaS Advisors, a division of Trinity Life Sciences, conducted 15 in-depth interviews with key decision-makers from advanced healthcare systems in the U.S. to understand their perspectives on what is driving IDNs and what they…
Read Now
Webinars
Available On Demand
Unlock forecasting value with revolutionary technology
Collaborate on and update models in the cloud
Incorporate stakeholder feedback into forecasts on the fly
Manage effective and efficient stakeholder communication
Trinity CloudCast is an online solution, delivered with Trinity’s best-in-class forecasting services, that streamlines forecasting activities to drive effective and efficient business decisions across life sciences organizations.
Come join us for a virtual discussion, where Susheel Sukhtankar, Partner & Head of Commercial Analytics, Adrian Watson, Director of Forecasting and Akash Kundu, Associate…
Watch Now
Webinars
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies…
Watch Now
Webinars
Available On Demand
The omnichannel-driven approach to promotional activity is being shaped by evolving dynamics in the life sciences market:
The behavior of the target audience is changing. Customers have an increased desire for personalized content and on-demand access.
Proliferation of data and AI is introducing more complexity to planning, execution and adoption of new ways of doing things.
Economic pressures and fear of message fatigue is leading promotional efforts to become more orchestrated and cost-efficient.
What considerations should life sciences organizations make…
Watch Now
Scientific Publications
Health Equity Frameworks – Healthcare System Actions and Priorities
Gulaid A1, Goldman E2, Skaar J1, Dehipawala S3
1Trinity Life Sciences, New York, NY, USA, 2Trinity Life Sciences, Waltham, MA, USA, 3Trinity Life Sciences, Bellerose, NY, USA
Health equity has been defined as attainment of the highest level of health for all people, regardless of race, ethnicity, disability, and/or other factors affecting access to care and health outcomes in healthcare delivery. Health equity is becoming a priority for payers and hospitals…
Read Now
Webinars
Available On Demand
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve while in parallel navigating new artificial intelligence (AI) and other general-purpose technologies (GPTs) technologies…
Watch Now
Blog
Published April 21, 2023
Executive Summary
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success.
In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window.
Trinity’s Take
These events usher in a new era for the life sciences industry, necessitating new thinking around development and commercialization strategy.
Historic reliance on the U.S. market…
Read Now
